Excaliard Release: RiverVest Venture Partners Sells Four Successful Life Science Companies for More than $1 Billion
2/7/2012 8:39:13 AM
More...
|
Pfizer Inc. (PFE) Completes Acquisition of Excaliard
12/2/2011 9:13:34 AM
More...
|
Isis Pharmaceuticals, Inc. (ISIS) to Receive Up to $14 Million from Pfizer Inc. (PFE) for Its Acquisition of Excaliard
11/22/2011 6:49:36 AM
More...
|
Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring
1/10/2011 7:25:36 AM
More...
|
Excaliard Appoints Thomas Wiggans to Chairman of the Board
10/18/2010 7:18:32 AM
More...
|
Excaliard Announces Positive Data From Phase 2 Clinical Trial of Its Anti-Scarring Drug, EXC 001
8/4/2010 8:42:34 AM
More...
|
Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001
1/5/2010 11:32:18 AM
More...
|
Excaliard, an Isis Pharmaceuticals, Inc. (ISIS) (JOBS) Spinoff With Anti-Scarring Drug, Marches Ahead in Clinical Trials
10/29/2009 7:29:52 AM
More...
|
Excaliard Contracts BioTox Sciences for Preclinical Research Services
11/6/2008 3:06:26 PM
More...
|
Excaliard Appoints Lincoln Krochmal, MD, President & Chief Executive Officer and Jeffrey Jenson, Head of Clinical Operations
10/10/2008 8:16:40 AM
More...
|
|